Abstract
The basis of breast cancer risk associated with hormonal therapies may lie in the regulation of cell proliferation. In a prospective, double-blind, randomized study postmenopausal women were given continuous combined hormone replacement therapy (HRT) either as estradiol valerate 2 mg/dienogest 2 mg, (E2V/DNG) or estradiol 2 mg/noretisterone acetate 1 mg (E2/NETA) for 6 months. Fine needle aspiration (FNA) biopsies were used for immunocytochemical analysis of breast cell proliferation before and during treatment. From 45 women completing the study 135 biopsies were obtained. In the total material there was a more than 4-fold increase in proliferation between baseline and 3 months (p < 0.001). The mean percentage of MIB-1 positive breast cells increased from 2.2 to 9.1%. In some individual women values were as high as 25%. No further increase was recorded at 6 months. While numerical values were somewhat lower in the E2V/DNG group, there were no significant differences between treatments. There was a positive correlation between breast cell proliferation (MIB-1%) and circulating levels of both estradiol (r s = 0.54, p < 0.01) and estrone (r s = 0.53, p < 0.01) after 3 and 6 months of treatment. No correlations with other endogenous hormones, proteins or with the two exogenous progestogens dienogest and norethisterone were observed. Increased breast cell proliferation should probably be regarded as an unwanted side-effect during HRT. Means to identify those women with the most pronounced proliferative response should be developed. The FNA biopsy technique may be a useful tool to monitor and evaluate the proliferative response to HRT in the normal breasts of postmenopausal women.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barret-Conner E: Hormonal replacement therapy. BMJ 317: 457-461, 1998
Collaborative group on Hormonal Factors in Breast Cancer: Breast Cancer and hormone replacement therapy: collaborative reanalysis of individual data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer from 54 epidemiological studies. Lancet 350: 1047-1059, 1997
Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE: Increased cell division as a cause of human cancer. Cancer Res 50: 7415-7421, 1990
Vihko R, Isomaa V: Endocrine aspects of endometrial cancer. In: Voight KD, Knabbe C, (eds) Endocrine Dependent Tumors. Raven Press, New York, 1989, pp 197-214
Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergström R, Lindgren A, Correia N, Persson I: Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91: 1131-1137, 1999
Santen RJ, Pinkerton J, McCartney C, Petroni GR: Risk of breast cancer with progestins in combination with estrogens as hormone replacement therapy. J Clin Endocrinol Metab 86: 16-23, 2001
Speroff L: Postmenopausal estrogen-progestin therapy and breast cancer: a clinical response to epidemiological reports. Climacteric 3: 3-12, 2000
Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84: 4559-4565, 1999
Franzén S, Zajicek J: Aspiration biopsy in diagnosis of palpable lesions of the breast. Acta Radiol 7: 241-262, 1968
Skoog L, Rutqvist LE, Wilking N: Analysis of hormone receptors and proliferation fraction in fine-needle aspirates from primary breast carcinomas during chemotherapy or tamoxifen treatment. Acta Oncol 31: 139-141, 1992
Söderqvist G, Isaksson E, von Schoultz B, Carlström K, Tani E, Skoog L: Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 176: 123-128, 1997
Isaksson E, von Schoultz E, Odlind V, Söderqvist G, Csemiczky G, Carlström K, Skoog L, von Schoultz B: Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 65: 163-169, 2001
Conner P, Skoog L, Söderqvist G: Breast epithelial proliferation in postmenopausal women evaluated through fine-needleaspiration cytology. Climateric 4: 7-12, 2001
Skoog L, Humla S, Isaksson S, Tani E: Immunocytochemical analysis of receptors for estrogen and progesterone in fine needle aspirates from human mammary carcinomas. Diagn Cytopathol 6: 95-98, 1990
Gerdes J, Li L, Schlueter C, Duchrow M, Whienberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138: 867-873, 1991
Lindberg BS, Lindberg P, Martinsson K, Johansson EDB: Radioimmunological methods for the estimation of estrone, estradiol-17β and estriol in pregnancy plasma. Acta Obstet Gynecol Scand (Suppl 32), 1974
Bedolla-Tovar N, Rahman SA, Cekan SZ, Diczfalusy E: Assessement of the specificity of norethisterone radioimmunoassay. J Steroid Biochem 9: 561-567, 1978
Kaufmann S, Linkert E: Analytical report dienogest. Study ME 97044. Jenapharm AG, Jena, Germany, 2000
Södergård R, Bäckström T, Shanbag V, Carstensen H: Calculation of free and bound fractions of testosterone and estradiol-17β to plasma proteins at body temperature. J Steroid Biochem 187: 801-804, 1982
Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90: 1292-1299, 1998
Boyd NF, Lockwood GA, Byng JW, Tritcher DL, Yaffe Mj: Mammographic densities and breast cancer risk. Cancer Epidemiol Biomark Prev 7: 1133-1144, 1998
Lundström E, Wilczek B, Von Palffy Z, Söderqvist G, von Schoultz B: Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 181: 348-353, 1999
Miller WR, Langson SP: Steroid hormones and cancer. II. Lessons from experimental systems. Eur J Surg Oncol 23: 163-183, 1997
Oettel M, Holz C: Hybrid Progestins-the example of dienogest. In: Sitruk-Ware R, Mishell DR (eds) Progestins and Antiprogestins in Clinical Practice. Marcel Dekker, New York, Basel, 2000, pp 163-178
Gräser T, Koytchev R, Muller A, Oettel M: Comparison of the efficacy and endometrial safety of two estradiol valerate/ dienogest combinations and Kliogest® for continuous combined hormone replacement therapy in postmenopausal women. Climacteric 3: 109-118, 2000
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396, 1998
Pye JK, Mansel RE, Hughes LE: Clinical experience of drug treatments for mastalgia. Lancet 2: 373-377, 1985
Zhou J, Ng S, Adesanya-Famuiya O, Andersson K, Bondy CA: Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 12: 1725-1730, 2000
Reid SE, Murthy MS, Kaufman M, Scanlon EF: Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 83: 1037-1046, 1996
Roger P, Sahla ME, Mäkelä S, Gustafsson JA, Baldet P, Rochefort H: Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res 61: 2537-2541, 2001
Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283: 485-491, 2000
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Conner, P., Söderqvist, G., Skoog, L. et al. Breast Cell Proliferation in Postmenopausal Women During HRT Evaluated Through Fine Needle Aspiration Cytology. Breast Cancer Res Treat 78, 159–165 (2003). https://doi.org/10.1023/A:1022987618445
Issue Date:
DOI: https://doi.org/10.1023/A:1022987618445